Milvexian fails to reduce cardiovascular events after acute coronary syndrome
Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and…
Artificial intelligence guides personalized treatment for heart patients
A landmark international study led by the University of Zurich has shown that artificial intelligence can assess patient…